 |
236 Diseases |  |
42 Trials |
|
42 Trials |  |
3908 News |  |
| «12...37383940414243444546474849» |
- |||| Herceptin (trastuzumab) / Roche
Enrollment open: Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer (clinicaltrials.gov) - Jun 11, 2012
P2, N=115, Recruiting, Sponsor: Nancy Lin, MD
Active, not recruiting --> Recruiting
- ||||| lapatinib / Generic mfg.
Trial initiation date, Metastases: LaMB: A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium (clinicaltrials.gov) - Jun 7, 2012
P2/3, N=204, Recruiting, Sponsor: Queen Mary University of London
Active, not recruiting --> Recruiting Initiation date: Nov 2007 --> Mar 2009
- lapatinib / Generic mfg., letrozole / Generic mfg.
Trial termination, Combination therapy: PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE (clinicaltrials.gov) - Jun 6, 2012
P2, N=6, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Initiation date: Nov 2007 --> Mar 2009 Active, not recruiting --> Terminated; slow accrual
- | lapatinib / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
New P2 trial, Surgery: Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery (clinicaltrials.gov) - Jun 3, 2012
P2, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
- ganitumab (AMG 479) / Takeda, ImmunityBio, Herceptin (trastuzumab) / Roche
Trial initiation date: Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab (clinicaltrials.gov) - May 23, 2012
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; slow accrual Initiation date: May 2012 --> Nov 2012
- ||| Avastin (bevacizumab) / Roche
Enrollment closed, Combination therapy, Metastases: Lapatinib and Bevacizumab for Metastatic Breast Cancer (clinicaltrials.gov) - May 16, 2012
P2, N=52, Active, not recruiting, Sponsor: GlaxoSmithKline
Initiation date: May 2012 --> Nov 2012 Completed --> Active, not recruiting
- |||| Herceptin (trastuzumab) / Roche
Biomarker, Trial completion: CHERLOB: Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer (clinicaltrials.gov) - May 16, 2012
P2b, N=121, Completed, Sponsor: GlaxoSmithKline
Completed --> Active, not recruiting Recruiting --> Completed
- ||||| lapatinib / Generic mfg., temozolomide / Generic mfg.
New P2 trial, Combination therapy: Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - May 2, 2012
P2, N=70, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
- lapatinib / Generic mfg.
Enrollment change: Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Apr 25, 2012
P1/2, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed N=54 --> 24
- lapatinib / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Metastases: Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov) - Apr 22, 2012
P1, N=25, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=54 --> 24 Recruiting --> Active, not recruiting
- lapatinib / Generic mfg., vinorelbine tartrate / Generic mfg.
Trial completion, Combination therapy, Metastases: Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 16, 2012
P1, N=22, Completed, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Enrollment open: Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA) (clinicaltrials.gov) - Apr 15, 2012
P2, N=80, Recruiting, Sponsor: German Breast Group
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| lapatinib / Generic mfg.
Enrollment closed: Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy (clinicaltrials.gov) - Apr 5, 2012
P2, N=60, Active, not recruiting, Sponsor: Quynh-Thu Le
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | lapatinib / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC (clinicaltrials.gov) - Apr 4, 2012
P2, N=12, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| pazopanib / Generic mfg.
Trial completion, Monotherapy: Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer (clinicaltrials.gov) - Apr 4, 2012
P3, N=163, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- lapatinib / Generic mfg.
Trial completion, Metastases: S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer (clinicaltrials.gov) - Apr 3, 2012
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | lapatinib / Generic mfg., paclitaxel / Generic mfg.
Enrollment closed: CALGB-40601: Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Mar 27, 2012
P3, N=305, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial termination, Combination therapy, Metastases: UCDCC#207: Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 26, 2012
P1, N=5, Terminated, Sponsor: University of California, Davis
Recruiting --> Active, not recruiting Recruiting --> Terminated; Lack of funding
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Enrollment change, Combination therapy, Metastases: UCDCC#207: Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 26, 2012
P1, N=5, Terminated, Sponsor: University of California, Davis
Recruiting --> Terminated; Lack of funding N=34 --> 5
- lapatinib / Generic mfg.
Trial termination, Circulating tumor cells, Tumor cell, Metastases: Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells (clinicaltrials.gov) - Mar 21, 2012
P2, N=23, Terminated, Sponsor: GlaxoSmithKline
N=34 --> 5 Recruiting --> Terminated
- lapatinib / Generic mfg.
Trial completion: Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer (clinicaltrials.gov) - Mar 18, 2012
P2, N=49, Completed, Sponsor: Eastern Cooperative Oncology Group
Recruiting --> Terminated Active, not recruiting --> Completed
- Capoxigem (apricoxib) / Adastra Pharma
Enrollment change: APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202) (clinicaltrials.gov) - Mar 12, 2012
P2, N=12, Terminated, Sponsor: Tragara Pharmaceuticals, Inc.
Active, not recruiting --> Completed N=120 --> 12
- lapatinib / Generic mfg.
Enrollment change: Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (clinicaltrials.gov) - Mar 4, 2012
P2, N=35, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
N=120 --> 12 N=24 --> 35
- Herceptin (trastuzumab) / Roche
Trial withdrawal: ELATE: Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer (clinicaltrials.gov) - Feb 29, 2012
P2, N=0, Withdrawn, Sponsor: GlaxoSmithKline
N=24 --> 35 Not yet recruiting --> Withdrawn
- Herceptin (trastuzumab) / Roche
Enrollment change: ELATE: Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer (clinicaltrials.gov) - Feb 29, 2012
P2, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Not yet recruiting --> Withdrawn N=164 --> 0
- Sutent (sunitinib) / Pfizer
Enrollment closed, Metastases: TSAP: Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study (clinicaltrials.gov) - Feb 29, 2012
P=N/A, N=45, Active, not recruiting, Sponsor: VU University Medical Center
N=164 --> 0 Recruiting --> Active, not recruiting
- ||| lapatinib / Generic mfg., vinorelbine tartrate / Generic mfg., capecitabine / Generic mfg.
Enrollment closed, Combination therapy, Metastases: VITAL: Lapatinib in Combination With Vinorelbine (clinicaltrials.gov) - Feb 29, 2012
P2, N=112, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
New P2 trial: Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA) (clinicaltrials.gov) - Feb 7, 2012
P2, N=80, Recruiting, Sponsor: German Breast Group
- | lapatinib / Generic mfg.
Trial completion: Neoadjuvant GW572016 to Treat Breast Cancer (clinicaltrials.gov) - Feb 2, 2012
P2, N=49, Completed, Sponsor: Baylor Breast Care Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Herceptin (trastuzumab) / Roche
New P3 trial: CTRIAL-IE (ICORG) 11-10: A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer (clinicaltrials.gov) - Feb 1, 2012
P3, N=600, Recruiting, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
- |||| Votrient (pazopanib) / Novartis, BeiGene
Trial completion, Combination therapy, Monotherapy, Metastases: Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer (clinicaltrials.gov) - Jan 19, 2012
P2, N=228, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial initiation date, Metastases: Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only (clinicaltrials.gov) - Jan 11, 2012
P1, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Initiation date: Mar 2011 --> Jan 2012
- Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment open, Metastases: Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only (clinicaltrials.gov) - Jan 11, 2012
P1, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Mar 2011 --> Jan 2012 Not yet recruiting --> Recruiting
- lapatinib / Generic mfg., paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment change: Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb (clinicaltrials.gov) - Jan 2, 2012
P1, N=13, Completed, Sponsor: Jungsil Ro
Not yet recruiting --> Recruiting N=18 --> 13
- lapatinib / Generic mfg.
Enrollment change: Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors (clinicaltrials.gov) - Jan 2, 2012
P2, N=52, Completed, Sponsor: National Cancer Institute (NCI)
N=18 --> 13 N=42 --> 52
- lapatinib / Generic mfg., paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb (clinicaltrials.gov) - Jan 2, 2012
P1, N=13, Completed, Sponsor: Jungsil Ro
N=42 --> 52 Recruiting --> Completed
- ||||| lapatinib / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
New P2 trial, Combination therapy, Metastases: Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer (clinicaltrials.gov) - Dec 22, 2011
P2, N=76, Recruiting, Sponsor: University of Maryland
- bortezomib / Generic mfg., lapatinib / Generic mfg.
New P1 trial, Metastases: Lapatinib and Bortezomib in Patients With Advanced Malignancies (clinicaltrials.gov) - Dec 20, 2011
P1, N=40, Recruiting, Sponsor: Georgetown University
- | oxaliplatin / Generic mfg., lapatinib / Generic mfg., capecitabine / Generic mfg.
Enrollment closed, Metastases: LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib (clinicaltrials.gov) - Dec 20, 2011
P3, N=545, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Active, not recruiting
- Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Herceptin (trastuzumab) / Roche
New P1/2 trial: The Myocet/Lapatinib Study. ICORG 10-03, V5 (clinicaltrials.gov) - Dec 18, 2011
P1/2, N=21, Recruiting, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
- | lapatinib / Generic mfg.
Enrollment open, Metastases: A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval (clinicaltrials.gov) - Dec 8, 2011
P4, N=48, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche
New P2 trial: ICORG 10-05: A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients. (clinicaltrials.gov) - Dec 4, 2011
P2, N=120, Active, not recruiting, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
- ||||| Herceptin (trastuzumab) / Roche
Enrollment closed: Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Dec 4, 2011
P3, N=652, Active, not recruiting, Sponsor: NCIC Clinical Trials Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| lapatinib / Generic mfg., capecitabine / Generic mfg.
Enrollment closed, Metastases: GERICO09: Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer. (clinicaltrials.gov) - Nov 28, 2011
P2, N=52, Active, not recruiting, Sponsor: UNICANCER
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ganitumab (AMG 479) / Takeda, ImmunityBio, Herceptin (trastuzumab) / Roche
New P1/2 trial: Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab (clinicaltrials.gov) - Nov 22, 2011
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
- Nerlynx (neratinib) / Puma
Enrollment closed, Metastases: Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer (clinicaltrials.gov) - Nov 21, 2011
P2, N=233, Active, not recruiting, Sponsor: Puma Biotechnology, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- metformin / Generic mfg., lapatinib / Generic mfg.
New P2 trial, Metastases: Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Nov 20, 2011
P2, N=32, Terminated, Sponsor: Fondazione Michelangelo
- || Herceptin (trastuzumab) / Roche
New P3 trial: ICORG 11-10 (TH v THL) A study to find out whether combining lapatinib treatment with trastuzumab and paclitaxel is more effective at slowing the growth of HER2 positive metastatic breast cancer, than using trastuzumab and paclitaxel alone. (EUDRACT) - Nov 17, 2011
P3, N=600, Ongoing, Sponsor: ICORG`ICORG -All Ireland Cooperative Oncology Research Group`All Ireland Cooperative Oncology Research Group (ICORG)
- dactolisib (RTB101) / Adicet Bio
New P2 trial: A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab (clinicaltrials.gov) - Nov 14, 2011
P2, N=5, Completed, Sponsor: Novartis Pharmaceuticals
- ||||| Herceptin (trastuzumab) / Roche
Enrollment closed: ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib (clinicaltrials.gov) - Nov 8, 2011
P3, N=63, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting